China Resources Pharmaceutical Group Ltd. (CHINARES PHARMA, stock code 03320) disclosed that its wholly owned subsidiary, China Resources Pharmaceutical Investment Co., has launched a public tender to dispose of approximately 5.88% equity in Tianmai Biotechnology Development Co., Ltd.

The proposed sale will be conducted on the Shanghai United Assets and Equity Exchange with an initial minimum listing price of about RMB0.51 billion. The tender process is separate from an earlier transaction involving Tianmai Biotechnology announced on 9 February 2026.

As at the announcement date, China Resources Pharmaceutical Investment and its subsidiary collectively hold around 23.75% of Tianmai Biotechnology. Identification of a transferee and execution of definitive agreements remain pending; if no transferee emerges, the tender will lapse automatically.

The company stated it will comply with Chapter 14 of the Hong Kong Listing Rules once transaction agreements, if any, are signed. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.